Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 200 of 456

1.
2.

Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats.

Franklin M, Hlavacova N, Li Y, Bermudez I, Csanova A, Sanchez C, Jezova D.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):499-502. doi: 10.1016/j.pnpbp.2017.08.008. Epub 2017 Aug 10.

PMID:
28802861
4.

Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia.

Yu ZH, Xu XH, Wang SD, Song MF, Liu Y, Yin Y, Mao HJ, Tang GZ.

Sleep Breath. 2017 Mar;21(1):191-195. doi: 10.1007/s11325-017-1462-0. Epub 2017 Jan 18.

PMID:
28101753
5.

Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
.

Chen R, Shen K, Hu P.

Int J Clin Pharmacol Ther. 2017 Mar;55(3):231-236. doi: 10.5414/CP202636.

PMID:
27936523
6.

Comparison of paroxetine and amitriptyline in the treatment of refractory globus pharyngeus.

Chen DY, Jia L, Gu X, Jiang SM, Xie HL, Xu J.

Dig Liver Dis. 2016 Sep;48(9):1012-7. doi: 10.1016/j.dld.2016.05.025. Epub 2016 Jun 11.

PMID:
27378704
7.

Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.

Rzezniczek S, Obuchowicz M, Datka W, Siwek M, Dudek D, Kmiotek K, Oved K, Shomron N, Gurwitz D, Pilc A.

Transl Psychiatry. 2016 May 31;6(5):e827. doi: 10.1038/tp.2016.90.

8.

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men.

Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ.

J Psychopharmacol. 2015 Oct;29(10):1085-91. doi: 10.1177/0269881115599387. Epub 2015 Aug 7.

9.

Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy.

Miskovic M.

Med Arch. 2015 Apr;69(2):107-9. doi: 10.5455/medarh.2015.69.107-109. Epub 2015 Apr 6.

10.

Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.

Chen R, Wang H, Shi J, Shen K, Hu P.

Eur J Clin Pharmacol. 2015 Jul;71(7):835-41. doi: 10.1007/s00228-015-1855-6. Epub 2015 May 13.

PMID:
25967538
11.

Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation.

Ozcan L, Polat EC, Otunctemur A, Ozbek E.

Int Urol Nephrol. 2015 Feb;47(2):283-7. doi: 10.1007/s11255-014-0905-9. Epub 2015 Jan 4.

PMID:
25557853
12.

Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.

Peselow ED, Tobia G, Karamians R, Pizano D, IsHak WW.

Psychiatry Res. 2015 Feb 28;225(3):680-6. doi: 10.1016/j.psychres.2014.11.022. Epub 2014 Nov 24.

PMID:
25496869
13.

Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting.

Jern P, Johansson A, Piha J, Westberg L, Santtila P.

Int J Impot Res. 2015 Mar-Apr;27(2):75-80. doi: 10.1038/ijir.2014.37. Epub 2014 Nov 20.

PMID:
25410962
14.

Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.

Chuang HY, Chang YH, Cheng LY, Wang YS, Chen SL, Chen SH, Chu CH, Lee IH, Chen PS, Yeh TL, Yang YK, Lu RB.

Chin J Physiol. 2014 Oct 31;57(5):265-70. doi: 10.4077/CJP.2014.BAC209.

PMID:
25241986
15.

Comparison of paroxetine and dapoxetine, a novel selective serotonin reuptake inhibitor in the treatment of premature ejaculation.

Simsek A, Kirecci SL, Kucuktopcu O, Ozgor F, Akbulut MF, Sarilar O, Ozkuvanci U, Gurbuz ZG.

Asian J Androl. 2014 Sep-Oct;16(5):725-7. doi: 10.4103/1008-682X.128467.

16.

Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.

Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A.

Int J Neuropsychopharmacol. 2014 Jun;17(6):859-69. doi: 10.1017/S1461145714000017. Epub 2014 Jan 23.

PMID:
24456909
17.

A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

Sanchez C, Reines EH, Montgomery SA.

Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review.

18.

Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.

Wang Y, Yu L, Xie J, Chen J, Wei Q.

Asia Pac Psychiatry. 2014 Dec;6(4):353-62. doi: 10.1111/appy.12106. Epub 2013 Oct 22. Review.

PMID:
24150924
19.

Comparison of escitalopram and paroxetine in the treatment of major depressive disorder.

Lin HL, Hsu YT, Liu CY, Chen CH, Hsiao MC, Liu YL, Shen WW, Hsiao CF, Liu SI, Chang LH, Tang HS, Lai HL, Lin PS, Lin KM, Tsou HH.

Int Clin Psychopharmacol. 2013 Nov;28(6):339-45. doi: 10.1097/YIC.0b013e32836458e2.

PMID:
23881184
20.

Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.

Gibiino S, Mori E, De Ronchi D, Serretti A.

J Clin Psychopharmacol. 2013 Aug;33(4):565-9. doi: 10.1097/JCP.0b013e3182905967.

PMID:
23764690
21.

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression.

Kamijima K, Hashimoto S, Nagayoshi E, Koyama T.

Neuropsychiatr Dis Treat. 2013;9:555-65. doi: 10.2147/NDT.S42915. Epub 2013 Apr 26. Erratum in: Neuropsychiatr Dis Treat. 2013;9:813.

22.

A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder.

Qu SS, Huang Y, Zhang ZJ, Chen JQ, Lin RY, Wang CQ, Li GL, Wong HK, Zhao CH, Pan JY, Guo SC, Zhang YC.

J Psychiatr Res. 2013 Jun;47(6):726-32. doi: 10.1016/j.jpsychires.2013.02.004. Epub 2013 Mar 14.

PMID:
23498306
23.

The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine.

Philbert J, Belzung C, Griebel G.

Psychopharmacology (Berl). 2013 Jul;228(1):97-107. doi: 10.1007/s00213-013-3020-1. Epub 2013 Feb 14.

PMID:
23407783
24.

5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.

Kato M, Nonen S, Serretti A, Tetsuo S, Takekita Y, Azuma J, Kinoshita T.

J Clin Psychopharmacol. 2013 Feb;33(1):131-2. doi: 10.1097/01.jcp.0000426182.66701.76. No abstract available.

PMID:
23288236
25.

Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?

Schilling C, Gilles M, Blum WF, Daseking E, Colla M, Weber-Hamann B, Lederbogen F, Krumm B, Heuser I, Wudy SA, Kopf D, Deuschle M.

J Clin Psychopharmacol. 2013 Feb;33(1):99-103. doi: 10.1097/JCP.0b013e31827cb179.

PMID:
23277262
26.

Comparison of the effectiveness of trauma-focused cognitive behavioral therapy and paroxetine treatment in PTSD patients: design of a randomized controlled trial.

Polak AR, Witteveen AB, Visser RS, Opmeer BC, Vulink N, Figee M, Denys D, Olff M.

BMC Psychiatry. 2012 Oct 9;12:166. doi: 10.1186/1471-244X-12-166.

27.

Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine.

Sugimoto Y, Tagawa N, Kobayashi Y, Mitsui-Saito K, Hotta Y, Yamada J.

Eur J Pharmacol. 2012 Dec 5;696(1-3):96-100. doi: 10.1016/j.ejphar.2012.09.030. Epub 2012 Oct 3.

PMID:
23041149
28.

Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.

Khatavkar UN, Shimpi SL, Jayaram Kumar K, Deo KD.

Drug Dev Ind Pharm. 2013 Aug;39(8):1175-86. doi: 10.3109/03639045.2012.682222. Epub 2012 May 21.

PMID:
22607046
29.

Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study.

Van Holten TC, Roest M, Riphagen J, Jansen C, Naarding P, Adriaansen HJ, De Groot PG, Remijn JA.

J Thromb Haemost. 2012 Jun;10(6):1177-9. doi: 10.1111/j.1538-7836.2012.04703.x. No abstract available.

30.

Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.

Saruwatari J, Yasui-Furukori N, Niioka T, Akamine Y, Takashima A, Kaneko S, Uno T.

J Clin Psychopharmacol. 2012 Apr;32(2):195-9. doi: 10.1097/JCP.0b013e318248ddb9.

PMID:
22367658
31.

A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine.

Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, Valença AM, Veras AB, Paes F, Sardinha A, Nascimento I, de-Melo-Neto VL, Dias GP, E Silva AC, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M.

J Clin Psychopharmacol. 2012 Feb;32(1):120-6. doi: 10.1097/JCP.0b013e31823fe4bd. Erratum in: J Clin Psychopharmacol. 2012 Apr;32(2):206.

PMID:
22198456
32.

Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.

Yasui-Furukori N, Nakagami T, Kaneda A, Inoue Y, Suzuki A, Otani K, Kaneko S.

Hum Psychopharmacol. 2011 Dec;26(8):602-8. doi: 10.1002/hup.1252. Epub 2011 Nov 21.

PMID:
22102561
33.

Effects of periadolescent fluoxetine and paroxetine on elevated plus-maze, acoustic startle, and swimming immobility in rats while on and off-drug.

Vorhees CV, Morford LR, Graham DL, Skelton MR, Williams MT.

Behav Brain Funct. 2011 Oct 5;7:41. doi: 10.1186/1744-9081-7-41.

34.

Therapeutic effect of paroxetine on stress-induced gastric lesions in mice.

Takahashi T, Suzuki G, Nibuya M, Tanaka T, Nozawa H, Hatano B, Takahashi Y, Shimizu K, Yamamoto T, Tachibana S, Nomura S.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):39-43. doi: 10.1016/j.pnpbp.2011.08.017. Epub 2011 Sep 10.

PMID:
21939725
35.

Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.

Parker RB, Soberman JE.

Pharmacotherapy. 2011 Jul;31(7):630-41. doi: 10.1592/phco.31.7.630.

PMID:
21923449
36.

A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.

Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Cui X, Calabrese JR, Gao K; OPERATION Study Team.

J Clin Psychopharmacol. 2011 Oct;31(5):638-42. doi: 10.1097/JCP.0b013e31822bb1d9.

PMID:
21869688
37.

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.

Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, Fujiwara T, Kitahara S, Katano T, Hara S.

Eur J Clin Pharmacol. 2012 Jan;68(1):29-37. doi: 10.1007/s00228-011-1094-4. Epub 2011 Jul 8.

38.

Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder.

Yasui-Furukori N, Tsuchimine S, Nakagami T, Fujii A, Sato Y, Tomita T, Yoshizawa K, Inoue Y, Kaneko S.

Hum Psychopharmacol. 2011 Apr;26(3):194-200. doi: 10.1002/hup.1192.

PMID:
21638327
39.

Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion.

Abler B, Seeringer A, Hartmann A, Grön G, Metzger C, Walter M, Stingl J.

Neuropsychopharmacology. 2011 Aug;36(9):1837-47. doi: 10.1038/npp.2011.66. Epub 2011 May 4.

40.

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.

Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R.

Support Care Cancer. 2012 Feb;20(2):375-84. doi: 10.1007/s00520-011-1118-8. Epub 2011 Mar 15.

41.

Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine.

Nardi AE, Valença AM, Freire RC, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, de O e Silva AC, Veras AB, Dias GP, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M.

J Clin Psychopharmacol. 2011 Apr;31(2):259-61. doi: 10.1097/JCP.0b013e318210b4ee. No abstract available.

PMID:
21364347
42.

Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter?

Klemp M, Tvete IF, Gåsemyr J, Natvig B, Aursnes I.

J Clin Psychopharmacol. 2011 Apr;31(2):201-6. doi: 10.1097/JCP.0b013e318210bac1.

PMID:
21346610
43.

Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?

Karanges E, Li KM, Motbey C, Callaghan PD, Katsifis A, McGregor IS.

Int J Neuropsychopharmacol. 2011 May;14(4):491-504. doi: 10.1017/S146114571100006X. Epub 2011 Feb 18.

PMID:
21329552
44.

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.

Kim JE, Yoon SJ, Kim J, Jung JY, Jeong HS, Cho HB, Shin E, Lyoo IK, Kim TS.

Int J Clin Pract. 2011 Mar;65(3):323-9. doi: 10.1111/j.1742-1241.2010.02624.x.

PMID:
21314870
45.

Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial.

Sunay D, Sunay M, Aydoğmuş Y, Bağbancı S, Arslan H, Karabulut A, Emir L.

Eur Urol. 2011 May;59(5):765-71. doi: 10.1016/j.eururo.2011.01.019. Epub 2011 Jan 18.

PMID:
21256670
46.

Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.

Schutters SI, van Megen HJ, Van Veen JF, Schruers KR, Westenberg HG.

Hum Psychopharmacol. 2011 Jan;26(1):72-6. doi: 10.1002/hup.1165. Epub 2011 Feb 9.

PMID:
23055414
47.

[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].

Chauvet-Gélinier JC.

Encephale. 2010 Oct;36(5):425-32. doi: 10.1016/j.encep.2010.08.001. Epub 2010 Oct 12. French.

PMID:
21035633
48.

Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine.

Spinhoven P, Van der Does AJ, Van Dijk E, Van Rood YR.

J Psychosom Res. 2010 Sep;69(3):227-35. doi: 10.1016/j.jpsychores.2010.02.005. Epub 2010 Mar 30.

PMID:
20708444
49.

A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder.

Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B.

World J Biol Psychiatry. 2010 Oct;11(7):904-13. doi: 10.3109/15622975.2010.489620.

PMID:
20602575
50.

Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.

Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X, Nierenberg AA; OPERATION Study Team.

J Clin Psychopharmacol. 2010 Aug;30(4):357-64. doi: 10.1097/JCP.0b013e3181e7784f.

PMID:
20571433
51.

Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study.

Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M.

J Affect Disord. 2010 Nov;126(3):453-7. doi: 10.1016/j.jad.2010.04.025. Epub 2010 Jun 12.

PMID:
20547424
52.

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.

Millan MJ, Dekeyne A, Gobert A, Mannoury la Cour C, Brocco M, Rivet JM, Di Cara B, Lejeune F, Cremers TI, Flik G, de Jong TR, Olivier B, de Nanteuil G.

Eur Neuropsychopharmacol. 2010 Sep;20(9):599-621. doi: 10.1016/j.euroneuro.2010.04.003. Epub 2010 May 18.

PMID:
20483567
53.

Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.

Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE.

J Clin Pharmacol. 2011 Mar;51(3):389-96. doi: 10.1177/0091270010365559. Epub 2010 Apr 16.

54.

Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation.

Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud el-HM, Amr M.

J Sex Med. 2010 Aug;7(8):2860-7. doi: 10.1111/j.1743-6109.2010.01789.x. Epub 2010 Mar 30.

PMID:
20367773
55.

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH; EMBOLDEN II (Trial D1447C00134) Investigators.

J Clin Psychiatry. 2010 Feb;71(2):163-74. doi: 10.4088/JCP.08m04942gre. Epub 2010 Jan 26.

PMID:
20122366
56.

Paroxetine mesylate: comparable to paroxetine hydrochloride?

Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS.

Expert Opin Pharmacother. 2010 Feb;11(2):185-93. doi: 10.1517/14656560903451708. Review.

PMID:
20088740
57.

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine.

Boulenger JP, Hermes A, Huusom AK, Weiller E.

Curr Med Res Opin. 2010 Mar;26(3):605-14. doi: 10.1185/03007990903482467.

PMID:
20067433
58.

[SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].

Rusconi AC, Carlone C, Muscillo M, Coccanari de' Fornari MA, Podda L, Piccione M.

Riv Psichiatr. 2009 Sep-Oct;44(5):313-9. Italian.

PMID:
20066819
59.

[SSRI discontinuation syndrome: incidence and differences on three groups of patients treated with paroxetine].

Rusconi AC, Carlone C, Muscillo M, Coccanari de' Fornari MA, Podda L, Piccione M.

Riv Psichiatr. 2009 May-Jun;44(3):169-75. Italian.

PMID:
20066803
60.

Comparison of antidepressant effects of azafan, tianeptine, and paroxetine.

Aleeva GN, Molodavkin GM, Voronina TA.

Bull Exp Biol Med. 2009 Jul;148(1):54-6.

PMID:
19902096
61.

Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study.

Wei F, Crain AL, Whitebird RR, Godlevsky OV, O'Connor PJ.

CNS Drugs. 2009 Oct;23(10):857-65. doi: 10.2165/11310840-000000000-00000.

PMID:
19739695
62.

Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition?

Kadioglu M, Muci E, Ozyavuz R, Yaris E, Kesim M, Kalyoncu NI.

Fundam Clin Pharmacol. 2010 Feb;24(1):55-61. doi: 10.1111/j.1472-8206.2009.00742.x. Epub 2009 Aug 21.

PMID:
19702694
63.

Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.

Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1451-3. doi: 10.1016/j.pnpbp.2009.07.028. Epub 2009 Aug 5.

PMID:
19664676
64.

Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up.

Greeven A, van Balkom AJ, van der Leeden R, Merkelbach JW, van den Heuvel OA, Spinhoven P.

J Behav Ther Exp Psychiatry. 2009 Sep;40(3):487-96. doi: 10.1016/j.jbtep.2009.06.005. Epub 2009 Jun 28.

PMID:
19616195
65.

Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.

Argyropoulos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, Wilson S.

J Sleep Res. 2009 Sep;18(3):342-8. doi: 10.1111/j.1365-2869.2008.00724.x. Epub 2009 Jun 22.

66.

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.

Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II.

BMC Psychiatry. 2009 May 26;9:25. doi: 10.1186/1471-244X-9-25.

67.

History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.

Pae CU, Masand PS, Marks DM, Krulewicz S, Peindl K, Mannelli P, Patkar AA.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):996-1002. doi: 10.1016/j.pnpbp.2009.05.005. Epub 2009 May 9.

PMID:
19433129
68.

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.

Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, Debonnel G.

Eur Neuropsychopharmacol. 2009 Jul;19(7):457-65. doi: 10.1016/j.euroneuro.2009.01.015. Epub 2009 Apr 2.

PMID:
19345072
69.

Superiority of escitalopram to paroxetine in the treatment of depression.

Kasper S, Baldwin DS, Larsson Lönn S, Boulenger JP.

Eur Neuropsychopharmacol. 2009 Apr;19(4):229-37. doi: 10.1016/j.euroneuro.2008.12.003. Epub 2009 Jan 29.

PMID:
19185467
70.

Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.

Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A.

J Clin Psychiatry. 2009 Jan;70(1):46-57. Epub 2008 Oct 7.

PMID:
19026248
71.

Paroxetine: safety and tolerability issues.

Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU.

Expert Opin Drug Saf. 2008 Nov;7(6):783-94. doi: 10.1517/14740330802423168 . Review.

PMID:
18983224
72.

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

Montejo AL, Prieto N, Terleira A, Matias J, Alonso S, Paniagua G, Naval S, Parra DG, Gabriel C, Mocaër E, Portolés A.

J Psychopharmacol. 2010 Jan;24(1):111-20. doi: 10.1177/0269881108096507. Epub 2008 Sep 18.

PMID:
18801825
73.

Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.

Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A.

Br J Clin Pharmacol. 2008 Nov;66(5):695-705. doi: 10.1111/j.1365-2125.2008.03261.x. Epub 2008 Jul 11.

74.

Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Lim KS, Cho JY, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, Yi S, Eum S, Shin SG, Yu KS.

Br J Clin Pharmacol. 2008 Nov;66(5):660-6. doi: 10.1111/j.1365-2125.2008.03267.x. Epub 2008 Jul 24.

75.

Strain differences in paroxetine-induced reduction of immobility time in the forced swimming test in mice: role of serotonin.

Guzzetti S, Calcagno E, Canetta A, Sacchetti G, Fracasso C, Caccia S, Cervo L, Invernizzi RW.

Eur J Pharmacol. 2008 Oct 10;594(1-3):117-24. doi: 10.1016/j.ejphar.2008.07.031. Epub 2008 Jul 24.

PMID:
18691569
76.

Common adverse events associated with an SSRI: meta-analysis of early paroxetine data.

Aursnes I, Gjertsen MK.

Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):707-13. doi: 10.1002/pds.1596.

PMID:
18383561
77.

The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial.

Iwamoto K, Takahashi M, Nakamura Y, Kawamura Y, Ishihara R, Uchiyama Y, Ebe K, Noda A, Noda Y, Yoshida K, Iidaka T, Ozaki N.

Hum Psychopharmacol. 2008 Jul;23(5):399-407. doi: 10.1002/hup.939.

PMID:
18383000
78.

Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols.

Wu KY, Liu CY, Hsiao MC.

Psychiatry Clin Neurosci. 2008 Feb;62(1):109-14. doi: 10.1111/j.1440-1819.2007.01785.x.

79.

Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.

Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH.

Psychopharmacology (Berl). 2008 May;197(4):675-81. doi: 10.1007/s00213-008-1087-x. Epub 2008 Feb 2.

PMID:
18246327
80.

Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study.

Safarinejad MR.

J Clin Psychopharmacol. 2008 Feb;28(1):39-44. doi: 10.1097/jcp.0b013e31816073a5.

PMID:
18204339
81.

beta-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder.

Lee IS, Kim KJ, Kang EH, Yu BH.

J Affect Disord. 2008 Sep;110(1-2):156-60. doi: 10.1016/j.jad.2007.12.007. Epub 2008 Jan 15.

PMID:
18199486
82.

Selective serotonin reuptake inhibitors fluvoxamine and paroxetine restore forced exercise-induced temperature dysregulation in ovariectomized mice.

Ikeda M, Egawa T, Yamauchi A, Sohda Y, Koga A, Tominaga K, Shuto H, Kataoka Y.

Eur J Pharmacol. 2008 Jan 28;579(1-3):439-44. Epub 2007 Nov 28.

PMID:
18155696
84.

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M.

Neuropsychobiology. 2007;56(2-3):73-85. Epub 2007 Nov 23.

PMID:
18037817
85.

A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.

Mazeh D, Shahal B, Aviv A, Zemishlani H, Barak Y.

Int Clin Psychopharmacol. 2007 Nov;22(6):371-5.

PMID:
17917556
86.

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):398-404. Epub 2007 Sep 15.

PMID:
17913323
87.

[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study].

Ji JL, Liu WJ, Zhang N, Chen ZQ, Zheng AL, Mei QY, Pan JY, Zhao ZX, Tao M, Wang YP, Wei J.

Zhonghua Yi Xue Za Zhi. 2007 Jun 19;87(23):1585-9. Chinese.

PMID:
17803844
88.
89.

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y.

Psychopharmacology (Berl). 2007 Oct;194(2):233-42. Epub 2007 Jun 23. Erratum in: Psychopharmacology (Berl). 2008 Feb;196(2):339. Zhang, Ying [added].

PMID:
17589833
90.
91.

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.

Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.

Psychiatry Clin Neurosci. 2007 Jun;61(3):295-307.

92.

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.

Book SW, Thomas SE, Randall PK, Randall CL.

J Anxiety Disord. 2008;22(2):310-8. Epub 2007 Mar 12.

93.

Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine.

Egashira N, Harada S, Okuno R, Matsushita M, Nishimura R, Mishima K, Iwasaki K, Orito K, Fujiwara M.

Eur J Pharmacol. 2007 Jun 1;563(1-3):149-54. Epub 2007 Feb 17.

PMID:
17349995
94.

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.

Int J Clin Pharmacol Ther. 2007 Jan;45(1):36-46.

PMID:
17256449
95.
96.

Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.

Morrens M, Wezenberg E, Verkes RJ, Hulstijn W, Ruigt GS, Sabbe BG.

J Clin Psychopharmacol. 2007 Feb;27(1):15-21.

PMID:
17224707
97.

Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine.

Naudon L, Hotte M, Jay TM.

Psychopharmacology (Berl). 2007 Apr;191(2):353-64. Epub 2007 Jan 12.

PMID:
17219219
98.

Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial.

Greeven A, van Balkom AJ, Visser S, Merkelbach JW, van Rood YR, van Dyck R, Van der Does AJ, Zitman FG, Spinhoven P.

Am J Psychiatry. 2007 Jan;164(1):91-9.

PMID:
17202549
99.

Effect of acute dapoxetine administration on the pudendal motoneuron reflex in anesthetized rats: comparison with paroxetine.

Giuliano F, Bernabé J, Gengo P, Alexandre L, Clément P.

J Urol. 2007 Jan;177(1):386-9.

PMID:
17162096
100.
101.

Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze.

Drapier D, Bentué-Ferrer D, Laviolle B, Millet B, Allain H, Bourin M, Reymann JM.

Behav Brain Res. 2007 Jan 25;176(2):202-9. Epub 2006 Nov 13.

PMID:
17095104
102.

Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom.

Jørgensen TR, Stein DJ, Despiegel N, Drost PB, Hemels ME, Baldwin DS.

Ann Pharmacother. 2006 Oct;40(10):1752-8. Epub 2006 Sep 19.

PMID:
16985090
104.

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.

Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.

Depress Anxiety. 2007;24(1):1-14.

PMID:
16894619
105.

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T.

Neuropsychobiology. 2006;53(4):186-95. Epub 2006 Jul 26.

PMID:
16874005
107.

RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine.

Tucker S, Ahl M, Cho HH, Bandyopadhyay S, Cuny GD, Bush AI, Goldstein LE, Westaway D, Huang X, Rogers JT.

Curr Alzheimer Res. 2006 Jul;3(3):221-7.

PMID:
16842099
108.

A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.

Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.

Curr Med Res Opin. 2006 Jul;22(7):1331-41.

PMID:
16834832
109.

Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.

Mullins CD, Shaya FT, Meng F, Wang J, Bron MS.

Clin Ther. 2006 Feb;28(2):297-305; discussion 296.

PMID:
16678651
110.
111.

Sexual function during bupropion or paroxetine treatment of major depressive disorder.

Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, Rafi-Tari S.

Can J Psychiatry. 2006 Mar;51(4):234-42.

PMID:
16629348
112.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626
113.

An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder.

Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):59-75.

PMID:
16553529
114.

The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine.

Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T.

Pharmacogenomics J. 2006 Sep-Oct;6(5):351-6. Epub 2006 Mar 14.

PMID:
16534507
116.

Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice.

Guilloux JP, David DJ, Guiard BP, Chenu F, Repérant C, Toth M, Bourin M, Gardier AM.

Neuropsychopharmacology. 2006 Oct;31(10):2162-72. Epub 2006 Jan 25.

117.

Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.

Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. Epub 2006 Feb 1.

PMID:
16448580
118.

Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.

Rickels K, Rynn M, Iyengar M, Duff D.

J Clin Psychiatry. 2006 Jan;67(1):41-7.

PMID:
16426087
119.

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients.

Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, Shimoda K.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):486-91. Epub 2006 Jan 18.

PMID:
16423440
120.

Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety.

McClendon J.

J Clin Psychiatry. 2005 Nov;66(11):1494-5; author reply 1495. No abstract available.

PMID:
16420094
121.

Intrafamilial correspondences on platelet [3H-]paroxetine-binding indices in bulimic probands and their unaffected first-degree relatives.

Steiger H, Gauvin L, Joober R, Israel M, Ng Ying Kin NM, Bruce KR, Richardson J, Young SN, Hakim J.

Neuropsychopharmacology. 2006 Aug;31(8):1785-92. Epub 2006 Jan 11.

122.

Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder.

Findling RL, Nucci G, Piergies AA, Gomeni R, Bartolic EI, Fong R, Carpenter DJ, Leeder JS, Gaedigk A, Danoff TM.

Neuropsychopharmacology. 2006 Jun;31(6):1274-85.

123.

Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients.

Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G, Lara N, Le Mellédo JM.

Neuropsychopharmacology. 2006 Jun;31(6):1286-93.

124.

Effect of gender on antinociceptive effect of paroxetine in hot plate test in mice.

Duman EN, Kesim M, Kadioglu M, Ulku C, Kalyoncu NI, Yaris E.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):292-6. Epub 2005 Nov 28.

PMID:
16316715
125.

A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.

Gruwez B, Dauphin A, Tod M.

J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):663-83.

PMID:
16307210
126.

[Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences].

Mosolov SN, Kostiukova EG, Gorodnichev AV, Timofeev IV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(10):22-9. Russian.

PMID:
16281375
127.

Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.

Roy-Byrne PP, Perera P, Pitts CD, Christi JA.

J Clin Psychiatry. 2005 Oct;66(10):1228-33.

PMID:
16259535
128.

Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder.

Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg HG.

Psychoneuroendocrinology. 2006 Apr;31(3):355-60. Epub 2005 Oct 24.

PMID:
16249058
129.

Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.

Baldwin D, Bridgman K, Buis C.

J Psychopharmacol. 2006 Jan;20(1):91-6. Epub 2005 Oct 4.

PMID:
16204325
130.

Effects of paroxetine and venlafaxine XR on heart rate variability in depression.

Davidson J, Watkins L, Owens M, Krulewicz S, Connor K, Carpenter D, Krishnan R, Nemeroff C.

J Clin Psychopharmacol. 2005 Oct;25(5):480-4.

PMID:
16160626
131.

Validation of a selective method for determination of paroxetine in human plasma by LC-MS/MS.

Massaroti P, Cassiano NM, Duarte LF, Campos DR, Marchioretto MA, Bernasconi G, Calafatti S, Barros FA, Meurer EC, Pedrazzoli J.

J Pharm Pharm Sci. 2005 Aug 17;8(2):340-7.

132.

Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats.

de Jong TR, Snaphaan LJ, Pattij T, Veening JG, Waldinger MD, Cools AR, Olivier B.

Eur Neuropsychopharmacol. 2006 Jan;16(1):39-48. Epub 2005 Aug 16.

PMID:
16107310
133.
134.

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder.

Bielski RJ, Bose A, Chang CC.

Ann Clin Psychiatry. 2005 Apr-Jun;17(2):65-9.

PMID:
16075658
135.

Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain.

Hirano K, Seki T, Sakai N, Kato Y, Hashimoto H, Uchida S, Yamada S.

Brain Res. 2005 Aug 16;1053(1-2):154-61.

PMID:
16051196
136.

Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.

Stein DJ, Andersen EW, Lader M.

Eur Neuropsychopharmacol. 2006 Jan;16(1):33-8. Epub 2005 Jul 12.

PMID:
16014329
137.

[Use of paroxetine on-demand in premature ejaculation].

Rivera P, González R, González F, Storme O.

Actas Urol Esp. 2005 Apr;29(4):387-91. Spanish.

PMID:
15981427
138.

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.

Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ.

J Clin Psychiatry. 2005 Jun;66(6):686-92.

PMID:
15960560
139.

Paroxetine serum concentrations in depressed patients and response to treatment.

Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Härtter S, Heuser I, Hiemke C.

Pharmacopsychiatry. 2005 May;38(3):118-21.

PMID:
15902581
140.

Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.

Mullins CD, Shaya FT, Meng F, Wang J, Harrison D.

Pharmacotherapy. 2005 May;25(5):660-7.

PMID:
15899727
141.

Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.

Gülseren L, Gülseren S, Hekimsoy Z, Mete L.

Arch Med Res. 2005 Mar-Apr;36(2):159-65.

PMID:
15847950
142.

Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.

Barbanoj MJ, Clos S, Romero S, Morte A, Giménez S, Lorenzo JL, Luque A, Dal-Ré R.

Neuropsychobiology. 2005;51(3):134-47. Epub 2005 Apr 18.

PMID:
15838185
143.

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T.

Int Clin Psychopharmacol. 2005 May;20(3):151-6.

PMID:
15812265
144.
145.

Do venlafaxine XR and paroxetine equally influence negative and positive affect?

Dichter GS, Tomarken AJ, Freid CM, Addington S, Shelton RC.

J Affect Disord. 2005 Apr;85(3):333-9.

PMID:
15780704
146.

Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.

Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R, Smith B.

Breast Cancer Res Treat. 2005 Feb;89(3):243-9.

PMID:
15754122
147.

Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine.

de Jong TR, Pattij T, Veening JG, Waldinger MD, Cools AR, Olivier B.

Psychopharmacology (Berl). 2005 May;179(2):509-15. Epub 2005 Feb 18.

PMID:
15719219
148.

Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment.

Keck ME, Sartori SB, Welt T, Müller MB, Ohl F, Holsboer F, Landgraf R, Singewald N.

J Neurochem. 2005 Mar;92(5):1170-9.

149.

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.

Szegedi A, Kohnen R, Dienel A, Kieser M.

BMJ. 2005 Mar 5;330(7490):503. Epub 2005 Feb 11. Erratum in: BMJ. 2005 Apr 2;330(7494):759. Dosage error in article text.

150.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
151.

Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.

Landén M, Högberg P, Thase ME.

J Clin Psychiatry. 2005 Jan;66(1):100-6.

PMID:
15669895
152.
153.

Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.

Sheehan DV, Burnham DB, Iyengar MK, Perera P; Paxil CR Panic Disorder Study Group.

J Clin Psychiatry. 2005 Jan;66(1):34-40.

PMID:
15669886
154.

The different roles of 5-HT(2) and 5-HT(3) receptors on antinociceptive effect of paroxetine in chemical stimuli in mice.

Kesim M, Duman EN, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N.

J Pharmacol Sci. 2005 Jan;97(1):61-6. Epub 2005 Jan 15.

155.

Risperidone and paroxetine given singly and in combination for bipolar depression.

Shelton RC, Stahl SM.

J Clin Psychiatry. 2004 Dec;65(12):1715-9.

PMID:
15641878
156.

Remission rates in patients with anxiety disorders treated with paroxetine.

Ballenger JC.

J Clin Psychiatry. 2004 Dec;65(12):1696-707.

PMID:
15641876
157.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
158.

The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder.

Schruers K, Griez E.

J Psychopharmacol. 2004 Dec;18(4):553-8.

PMID:
15582922
159.

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E.

Hum Psychopharmacol. 2004 Dec;19(8):585-6. No abstract available.

PMID:
15570574
161.

A comparative study of milnacipran and paroxetine in outpatients with major depression.

Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A; study co-coordinators.

J Affect Disord. 2004 Dec;83(2-3):233-6.

PMID:
15555719
162.

Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.

Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J.

Clin Ther. 2004 Sep;26(9):1446-55.

PMID:
15531007
163.

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.

Szegedi A, Rujescu D, Tadic A, Müller MJ, Kohnen R, Stassen HH, Dahmen N.

Pharmacogenomics J. 2005;5(1):49-53.

PMID:
15520843
164.

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.

Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A.

Arch Gen Psychiatry. 2004 Nov;61(11):1153-62.

PMID:
15520363
165.

Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.

Morishita S, Arita S.

Eur Psychiatry. 2004 Nov;19(7):450-1. No abstract available.

PMID:
15504656
166.

The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial.

Misri S, Reebye P, Corral M, Milis L.

J Clin Psychiatry. 2004 Sep;65(9):1236-41.

PMID:
15367052
167.
168.

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.

Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L.

Pharmacopsychiatry. 2004 Sep;37(5):206-10.

PMID:
15359375
169.

Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.

Wilson SJ, Bailey JE, Rich AS, Adrover M, Potokar J, Nutt DJ.

Eur Neuropsychopharmacol. 2004 Oct;14(5):367-72.

PMID:
15336297
170.
171.

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.

Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G; SAD 388 Study Group.

Hum Psychopharmacol. 2004 Aug;19(6):387-96.

PMID:
15303242
172.

Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998.

Leon AC, Marzuk PM, Tardiff K, Teres JJ.

J Clin Psychiatry. 2004 Jul;65(7):915-8.

PMID:
15291679
173.

Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine.

Morishita S, Arita S.

Eur Psychiatry. 2004 Aug;19(5):315-6. No abstract available.

PMID:
15276667
174.
175.

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.

Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA.

J Clin Psychopharmacol. 2004 Aug;24(4):389-99.

PMID:
15232330
176.

Three year naturalistic outcome study of panic disorder patients treated with paroxetine.

Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M.

BMC Psychiatry. 2004 Jun 11;4:16.

178.

What has dry cough in common with pruritus? Treatment of dry cough with paroxetine.

Zylicz Z, Krajnik M.

J Pain Symptom Manage. 2004 Feb;27(2):180-4.

PMID:
15157042
179.
180.

Paroxetine in major depression: correlating plasma concentrations and clinical response.

Normann C, Hörn M, Hummel B, Grunze H, Walden J.

Pharmacopsychiatry. 2004 May;37(3):123-6.

PMID:
15138896
181.

Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial.

Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G.

Am J Gastroenterol. 2004 May;99(5):914-20.

PMID:
15128360
182.

Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study.

Perna G, Bertani A, Caldirola D, Di Pasquale D, Migliarese G, Bellodi L.

J Clin Psychopharmacol. 2004 Jun;24(3):277-82.

PMID:
15118481
183.

Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.

Calvo G, García-Gea C, Luque A, Morte A, Dal-Ré R, Barbanoj M.

J Clin Psychopharmacol. 2004 Jun;24(3):268-76.

PMID:
15118480
184.

The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.

Romeo R, Patel A, Knapp M, Thomas C.

Int Clin Psychopharmacol. 2004 May;19(3):125-34.

PMID:
15107654
186.

Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison.

Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM.

J Clin Psychiatry. 2004 Mar;65(3):405-13.

PMID:
15096081
187.

Prenatal cocaine exposure potentiates paroxetine-induced desensitization of 5-HT2A receptor function in adult male rat offspring.

Chen Z, Waimey K, Van de Kar LD, Carrasco GA, Landry M, Battaglia G.

Neuropharmacology. 2004 Jun;46(7):942-53.

PMID:
15081791
188.

Paroxetine retards disease onset and progression in Huntingtin mutant mice.

Duan W, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP.

Ann Neurol. 2004 Apr;55(4):590-4.

PMID:
15048901
189.

Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients.

Straneva-Meuse PA, Light KC, Allen MT, Golding M, Girdler SS.

J Affect Disord. 2004 Apr;79(1-3):51-61.

PMID:
15023480
191.
192.

Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine: preliminary findings.

Szeszko PR, MacMillan S, McMeniman M, Lorch E, Madden R, Ivey J, Banerjee SP, Moore GJ, Rosenberg DR.

Neuropsychopharmacology. 2004 Apr;29(4):826-32.

193.

Paroxetine-induced hyponatremia in older adults: a 12-week prospective study.

Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, Bensasi SG, Weber E, Dew MA, Reynolds CF 3rd, Pollock BG.

Arch Intern Med. 2004 Feb 9;164(3):327-32.

PMID:
14769630
194.
195.
196.

Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.

Morishita S, Arita S.

Eur Psychiatry. 2003 Dec;18(8):418-20. No abstract available.

PMID:
14680720
197.

Paroxetine influences respiration in rats: implications for the treatment of panic disorder.

Olsson M, Annerbrink K, Bengtsson F, Hedner J, Eriksson E.

Eur Neuropsychopharmacol. 2004 Jan;14(1):29-37.

PMID:
14659984
199.
200.

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.

Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB; Paroxetine OCD Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1113-21.

PMID:
14628989

Supplemental Content

Loading ...
Support Center